Timing of Biologic Initiation After Starting LTBI Treatment

Risk Stratification for Timing Decision

For patients with latent TB at low risk for reactivation starting TNF-alpha inhibitors, the American College of Dermatology recommends initiating biologic therapy after at least 1 month of LTBI treatment 1
For high-risk patients, the American College of Dermatology recommends completing the full course of LTBI treatment before starting biologics, as high-risk features include close TB contacts, recent immigrants from high-incidence areas, intravenous drug users, and patients from endemic areas 1, 2

For patients with latent TB at high risk for reactivation, consider non-TNF biologics (IL-17 or IL-12/23 inhibitors) which can be started concomitantly with LTBI treatment, as secukinumab (anti-IL-17) and ustekinumab (anti-IL-12/23) show no increased risk of latent TB reactivation in multiple cohort studies 1, 2

A 4-month rifampin course is as effective as 9-month isoniazid with superior completion rates, lower cost, and better safety, according to the American Academy of Dermatology 1, 2
A 9-month isoniazid course remains an alternative option, as stated by the European Crohn's and Colitis Organisation 3
A 3-month rifapentine plus isoniazid course is not inferior to 9-month isoniazid with better adherence, according to the European Crohn's and Colitis Organisation 3

The European Crohn's and Colitis Organisation recommends delaying biologic therapy for at least 4 weeks after starting LTBI chemotherapy, except in cases of greater clinical urgency 3, 4
The British Association of Dermatologists recommends completing 2 months of LTBI treatment before commencing biologic therapy, although this is superseded by the 2025 guidelines 5

Do not delay biologic therapy unnecessarily in low-risk patients beyond 1 month of LTBI treatment, as this increases disease burden without additional safety benefit, according to the American College of Dermatology 1
Do not start TNF-alpha inhibitors in high-risk patients before completing LTBI treatment, as this significantly increases reactivation risk, according to the American College of Dermatology 1, 2
Do not forget to consider non-TNF biologics as an alternative that eliminates waiting time in high-risk patients, according to the American College of Dermatology 1, 2

For patients with active TB requiring biologics, complete antibacterial treatment with symptom resolution before biologic (re)initiation, and consider using non-TNF biologics where possible, according to the American College of Dermatology 1, 2

A reactive TB Gold test indicates latent tuberculosis infection in the absence of active TB, as seen in patients with autoimmune diseases such as lupus and RA 6
Normal chest X-ray rules out active pulmonary TB but is consistent with latent TB in immunosuppressed patients 6, 7
The absence of respiratory symptoms further supports latent rather than active TB in patients with positive TB screening tests 8
Underlying autoimmune conditions, such as lupus and RA, and treatment with biologic agents like Orencia, contribute to immunosuppression and increased risk of TB reactivation 6

The American College of Rheumatology recommends treating LTBI in immunocompromised patients with a positive TB screening test to prevent progression to active TB disease 6, 9
Treatment of LTBI is strongly indicated in patients with positive TB Gold tests and immunosuppression from both underlying diseases and biologic therapy 6, 9
Recommended regimens for LTBI treatment include isoniazid for 9 months and rifampin for 4 months, with monitoring for hepatotoxicity essential during treatment 10

Patients on biologics with LTBI should receive treatment before continuing biologic therapy, according to the American College of Rheumatology guidelines 6, 9
Treatment with biologics can be initiated or resumed after 1 month of latent TB treatment, as recommended by the American College of Rheumatology 9
Annual TB screening should be considered if the patient has ongoing risk factors for TB exposure, as suggested by the American College of Rheumatology 9

Monitoring for clinical symptoms rather than repeat testing is recommended for future surveillance in patients who test positive for TB Gold at baseline 9
Patients with autoimmune diseases on immunosuppressive therapy may have false-negative TB screening results, but this patient already has a positive test 6